Status:
COMPLETED
VK2735 for Weight Management Phase 2
Lead Sponsor:
Viking Therapeutics, Inc.
Conditions:
Weight Loss
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokine...
Eligibility Criteria
Inclusion
- Age ≥18 years of age at the time of signing the informed consent
- Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated), and BMI \<50 kg/m2
Exclusion
- History of or current clinically significant medical or psychiatric disorder that, in the opinion of the Investigator, does not support study participation
- Self-reported body weight change of 5% or more within 3 months of screening
- Current or past diagnosis of diabetes mellitus (including type 1, type 2, gestational)
- Current or past diagnosis of chronic pancreatitis
- Calcitonin ≥20 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)
- Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening
- Any prescription or over-the-counter medications intended for weight loss within 6 months of screening
Key Trial Info
Start Date :
August 31 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 2 2024
Estimated Enrollment :
176 Patients enrolled
Trial Details
Trial ID
NCT06068946
Start Date
August 31 2023
End Date
April 2 2024
Last Update
February 12 2025
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Viking Clinical Site #119
Birmingham, Alabama, United States, 35235
2
Viking Clinical Site #114
Long Beach, California, United States, 90815
3
Viking Clinical Site #110
Los Angeles, California, United States, 90057
4
Viking Clinical Site #113
Tustin, California, United States, 92780